NSC 90469

Synonyms: 3,5-二碘-L-甲状腺素; 3,5-Diiodo-L-thyronine
NSC 90469 (3,5-Diiodo-L-thyronine) 是一种具有口服活性的甲状腺激素衍生物,可抑制 JNK 磷酸化和 NF-κB 乙酰化,阻止 SIRT1 蛋白表达,诱导 PGC-1α 水平升高并刺激 COX 活性,同时增强 UCP1 介导的产热作用,提高肝脏 Dio1 活性,抑制 TSH 水平及下丘脑-垂体-甲状腺轴功能,增强脂质代谢,并通过线粒体途径调控能量代谢;此外,NSC 90469 可防止血糖降低,减少尿白蛋白排泄,抑制肾基质扩张,降低 TGF-β1 表达,减少肾脏纤连蛋白和 Ⅳ 型胶原 (Collagen) 沉积,还可提高能量消耗并预防饮食诱导的超重,因此可用于糖尿病肾病、甲状腺功能减退症、非酒精性脂肪性肝病及饮食诱导肥胖症的相关研究。
产品编号: MS-V98988 纯度: 99.41% CAS No.: 1041-01-6 分子式: C15H13I2NO4 分子量: 525.08
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

NSC 90469 (3,5-Diiodo-L-thyronine) 是一种具有口服活性的甲状腺激素衍生物,可抑制 JNK 磷酸化和 NF-κB 乙酰化,阻止 SIRT1 蛋白表达,诱导 PGC-1α 水平升高并刺激 COX 活性,同时增强 UCP1 介导的产热作用,提高肝脏 Dio1 活性,抑制 TSH 水平及下丘脑-垂体-甲状腺轴功能,增强脂质代谢,并通过线粒体途径调控能量代谢;此外,NSC 90469 可防止血糖降低,减少尿白蛋白排泄,抑制肾基质扩张,降低 TGF-β1 表达,减少肾脏纤连蛋白和 Ⅳ 型胶原 (Collagen) 沉积,还可提高能量消耗并预防饮食诱导的超重,因此可用于糖尿病肾病、甲状腺功能减退症、非酒精性脂肪性肝病及饮食诱导肥胖症的相关研究。

生物实验数据

生物活性 NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative that inhibits JNK phosphorylation and NF-κB acetylation, prevents SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity, while enhancing UCP1-mediated thermogenesis, increasing hepatic Dio1 activity, suppressing TSH levels and hypothalamic-pituitary-thyroid axis function, enhancing lipid metabolism, and regulating energy metabolism through the mitochondrial pathway; furthermore, NSC 90469 prevents blood glucose reduction, decreases urinary albumin excretion, inhibits renal matrix expansion, reduces TGF-β1 expression, and decreases renal fibronectin and type Ⅳ collagen (Collagen) deposition, and it also increases energy expenditure and prevents diet-induced overweight, making it useful for research on diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.
IC50 & Target

SIRT1

 

Collagen IV

 

体外研究
(In Vitro)

NSC 90469 (T2) (100 μM; 1-24 h) 可减弱高糖诱导的促纤维化改变,恢复 SIRT1 的表达与活性,并抑制大鼠肾小球系膜细胞中 NF-κB 的乙酰化及 JNK 的磷酸化。
NSC 90469 (10-12-10-6 M; 30 min) 可剂量依赖性地刺激甲状腺功能减退大鼠棕色脂肪组织匀浆中的细胞色素氧化酶活性,其半最大效应浓度为 10-11 M,最大激活浓度为 10-8 M。
NSC 90469 (0.1 nM-10000 nM; 24 h) 在 GH3 细胞中表现出差异性甲状腺模拟活性,可刺激 GH mRNA,同时下调 TRβ2 mRNA 的表达。
NSC 90469 (10-5 M) 可通过招募脂肪甘油三酯脂肪酶 (ATGL)、刺激线粒体功能及调控脂质相关蛋白表达,减少暴露于 Oleic acid(MS-M89265)/Palmitic acid (MS-A29753) 的原代大鼠肝细胞内的脂质过剩。
NSC 90469 (10-7-10-5 M; 24 h) 可通过非受体介导的机制,减少暴露于 Oleic acid(MS-M89265)/Palmitic acid (MS-A29753) 的 FAO 大鼠肝癌细胞中的脂质蓄积并刺激线粒体解偶联。
NSC 90469 可通过激活多种激酶通路阻断 SREBP-1 的蛋白水解切割,从而抑制 HepG2 细胞中的脂质合成。
NSC 90469 可调节垂体 GH3 细胞内的 Ca2+ 和 NO 水平,通过质膜与线粒体的相互作用激活线粒体 Na+/Ca2+ 交换体。
NSC 90469 (0.3 nM; 5 min) 可刺激金鱼 Carassius auratus 离体肝脏和肌肉中的线粒体呼吸作用。

体内研究
(In Vivo)

NSC 90469 (0.25 mg/kg,腹腔注射,每日 1 次,持续 12 周) 可改善 Streptozotocin (MS-Q80520) 诱导的雄性 Sprague-Dawley 大鼠糖尿病肾病,将血糖降至 6.3 mM,将尿白蛋白/肌酐比值降至 68.4 μg/mg,并恢复肾 SIRT1 的活性与表达。
NSC 90469 (3,5-二碘-L-甲状腺原氨酸)(250 μg/kg,腹腔注射;每日 1 次;持续 1 周) 在甲状腺功能减退的 Wistar 大鼠中可使静息能量消耗增加 13%,并通过增强线粒体功能、交感神经支配及血管生成,同时促进多泡棕色脂肪细胞表型来激活棕色脂肪组织产热,且不影响血清 T3/T4 水平。
NSC 90469 (100 µg/kg,腹腔注射;单次给药) 可提高暴露于低温环境中的甲状腺功能减退大鼠的耐寒能力,增加其能量消耗并延长存活时间。
NSC 90469 (250 µg/kg;每日给药;持续 4 周) 可预防大鼠中高脂饮食 (HFD) 诱导的肥胖、肝脏脂质蓄积、高脂血症及胰岛素抵抗,且不会引发甲状腺毒症。
NSC 90469 (1.25 mg/100 g 体重;口服;每日) 可使西式饮食喂养的 Ldlr 基因敲除小鼠的总胆固醇和低密度脂蛋白 (LDL) 胆固醇降低 70%。

Animal Model: Sprague-Dawley (male, 8-10 weeks old, initial body weight ~200 g, streptozotocin-induced diabetic)
Dosage: 0.25 mg/kg
Administration: i.p.; daily; 12 weeks
Result: Reduced kidney weight/body weight ratio to 6.1 mg/g, compared to 13.6 mg/g in untreated diabetic rats.
Lowered blood glucose to 6.3 mM/L, compared to 22.1 mM/L in untreated diabetic rats.
Decreased 24-hour total urine protein to 13.5 mg, compared to 52.7 mg in untreated diabetic rats.
Reduced urine albumin to 20.7 μg/dL, compared to 29.7 μg/dL in untreated diabetic rats.
Lowered urine albumin/creatinine ratio to 68.4 μg/mg, compared to 108.3 μg/mg in untreated diabetic rats.
Attenuated glomerulosclerosis index and renal fibrosis percentage, compared to untreated diabetic rats.
Increased renal SIRT1 protein expression and activity, compared to untreated diabetic rats.
Reduced renal mRNA and protein levels of TGF-β1, fibronectin, and collagen IV, compared to untreated diabetic rats.
Suppressed renal acetylated NF-κB and phosphorylated JNK levels, compared to untreated diabetic rats.
Animal Model: Wistar rats (male, 275-300 g, hypothyroidism induced by 4 weeks of intraperitoneal injection of 1 mg/100 g body weight propylthiouracil plus weekly intraperitoneal injection of 6 mg/100 g body weight iopanoic acid)
Dosage: 250 μg/kg
Administration: i.p.; daily; 1 week; i.p.; single dose 1 hour before euthanasia
Result: Increased resting energy expenditure by 13% compared to untreated hypothyroid rats.
Raised brown adipose tissue contribution to total body weight by 31% compared to untreated hypothyroid rats.
Increased multilocular adipocyte percentage to 78% (from 59% in untreated hypothyroid rats).
Reduced unilocular adipocyte percentage to 2% (from 10% in untreated hypothyroid rats).
Decreased multilocular adipocyte area by 29% compared to untreated hypothyroid rats.
Decreased lipid droplet diameter by 38% compared to untreated hypothyroid rats.
Increased sympathetic innervation (TH immunoreactive fibers per adipocyte) by 140% compared to untreated hypothyroid rats.
Increased vascularization (BS-1 positive capillaries per adipocyte) by 43% compared to untreated hypothyroid rats.
Increased mitochondrial content by 35% compared to untreated hypothyroid rats.
Increased cytochrome oxidase (COX) activity by 65% compared to untreated hypothyroid rats, restoring it to euthyroid levels.
Restored citrate synthase activity and VDAC1 content to euthyroid levels from untreated hypothyroid rat reductions.
Increased α-glycerophosphate-energized mitochondrial respiration by 70% in whole brown adipose tissue homogenates compared to untreated hypothyroid rats.
Increased basal respiration by 30% in isolated mitochondria compared to untreated hypothyroid rats.
Increased arachidonic acid-induced respiration (at 180 μM) by 62% compared to baseline in treated rats, a greater response than the 31% increase in untreated hypothyroid rats.
Increased UCP1 protein levels compared to untreated hypothyroid rats.
Induced a transient increase in nuclear PGC-1α levels with a single injection 1 hour before euthanasia.
Increased mitochondrial PGC-1α levels to euthyroid levels with 1 week of daily administration.
Did not affect serum T3/T4 levels, which remained significantly lower than euthyroid levels.
Animal Model: (hypothyroid, P+I-induced)
Dosage: 100 µg/kg
Administration: i.p.; single dose
Result: Extended survival from 3-4 days to 3 weeks during cold exposure.
Increased energy expenditure and tissue-specific oxidative capacity.
Animal Model: (high-fat diet-induced overweight)
Dosage: 250 µg/kg
Administration: daily; 4 weeks
Result: Prevented body weight gain, liver adiposity, hyperlipidemia, and insulin resistance.
Detected no signs of thyrotoxicosis (tachycardia, cardiac hyperplasia, decreased thyroid stimulating hormone levels).
Animal Model: Ldlr knockout (fed Western-type diet)
Dosage: 1.25 mg/100 g body weight
Administration: p.o.; daily
Result: Reduced circulating total and LDL cholesterol by 70% compared to controls.
Reduced liver apoB levels and circulating apoB48 and apoB100 levels.
Reduced plasma T4 levels and caused signs of thyrotoxicosis.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 525.08
分子式 C15H13I2NO4
CAS No. 1041-01-6
别名 3,5-二碘-L-甲状腺素; 3,5-Diiodo-L-thyronine

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (47.61 mM; ultrasonic and adjust pH to 2 with 1 M HCL; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 22.22 mg/mL (42.32 mM; ultrasonic and adjust pH to 2 with 1M HCl)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol / DMSO1 mM1.9045 mL9.5224 mL19.0447 mL47.6118 mL
5 mM0.3809 mL1.9045 mL3.8089 mL9.5224 mL
10 mM0.1904 mL0.9522 mL1.9045 mL4.7612 mL
15 mM0.1270 mL0.6348 mL1.2696 mL3.1741 mL
20 mM0.0952 mL0.4761 mL0.9522 mL2.3806 mL
25 mM0.0762 mL0.3809 mL0.7618 mL1.9045 mL
30 mM0.0635 mL0.3174 mL0.6348 mL1.5871 mL
40 mM0.0476 mL0.2381 mL0.4761 mL1.1903 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础